Malaysia Pharmaceuticals & Healthcare Report

Published 24 March 2015

  • 142 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Malaysia Pharmaceuticals & Healthcare Report

BMI View: Commercial opportunities for private healthcare providers in Malaysia will be buoyed by the robust growth in the country's medical tourism industry. Driven by strong demand from Asia and the weakening currency, we highlight that this trend will also create revenue prospects for innovative pharmaceutical companies. However, the implementation of the Goods and Service Tax (GST) on April 1st poses a downside risk to our forecast as the government seeks to introduce price control measures on non-exempt high value medicines.

Headline Expenditure Projections

  • Pharmaceuticals: MYR7.22bn (USD2.21bn) in 2014 to MYR7.88bn (USD2.24bn) in 2015; +9.2 % in local currency and +1.5% in US dollar terms.

  • Healthcare: MYR43.82bn (USD13.39bn) in 2014 to MYR47.64bn (USD13.53bn) in 2015; +8.7% in local currency and +1.1% in US dollar terms.

Risk/Reward Index

Malaysia's Pharmaceutical Risk/Reward Index score for Q215 is 62.1 out of 100. Moving up one position from last quarter, the country is now the seventh most attractive pharmaceutical market in the Asia Pacific region. It posts above-average scores for every indicator.

Key Trends And Developments

February 2015

  • Consumer groups in Malaysia have raised concerns over a new dispensing separation system scheduled to start from April 1 2015. The groups believe that the new system will create problems for the public on various fronts and fear higher costs will be implemented once doctors stop dispensing medicines themselves. Consumers would potentially be charged twice, once for doctor's consultation fees and later for the actual medicines from pharmacies, according to the Muslim Consumer Association of Malaysia chief activist Datuk Nadzim Johan. The new system reportedly replicates the national healthcare service of developed nations such as the US and the UK, and will only allow pharmacies to dispense prescription drugs, which were previously done in clinics.

January 2015

  • The growing online pharmaceutical industry and...

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
13
Business Environment
15
Industry Forecast
17
Pharmaceutical Market Forecast
17
Table: Pharmaceutical Sales, Historical Data And Forecasts (Malaysia 2010-2018)
19
Healthcare Market Forecast
20
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2010-2018)
21
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2010-2018)
22
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Malaysia 2010-2018)
22
Prescription Drug Market Forecast
23
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Malaysia 2010-2018)
24
Patented Drug Market Forecast
25
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Malaysia 2010-2018)
26
Generic Drug Market Forecast
27
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Malaysia 2010-2018)
28
OTC Medicine Market Forecast
29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Malaysia 2010-2018)
30
Pharmaceutical Trade Forecast
31
Table: Pharmaceutical Trade Data And Forecasts (Malaysia 2012-2018)
33
Table: Pharmaceutical Trade Data And Forecasts local currency (Malaysia 2012-2018)
34
Other Healthcare Data
35
Key Risks To BMI's Forecast Scenario
36
Macroeconomic Forecasts
38
Table: Economic Activity (Malaysia 2009-2018)
43
Industry Risk Reward Ratings
44
Asia Pacific Risk/Reward Ratings
44
Malaysia Risk/Reward Ratings
50
Rewards
50
Risks
51
Market Overview
52
Industry Trends And Developments
54
Epidemiology
54
Healthcare Sector
58
Table: 2011 Entry Points Projects Summary
60
Healthcare Insurance
61
Table: Main Features Of 1Care
61
Healthcare Funding
63
Healthcare Sector Developments
64
Table: Public Sector And Private Sector Healthcare Developments
64
Medical Tourism
65
Research & Development
67
Clinical Trials
69
Regulatory Development
71
Regulatory Regime
71
Table: Drug Applications by Type, 2002-2010
73
Table: Registered Pharmaceutical Products by Type, 2002-10
73
Regulatory Developments
74
Intellectual Property Issues
78
Pricing Regime
83
Competitive Landscape
85
Domestic Industry
85
Foreign Industry
87
Table: Leading Malaysian Pharmaceutical And Healthcare Companies
89
Culture-Specific Medicines
90
Pharmaceutical Distribution
93
Table: Drug Wholesalers & Importers, 2002-2010
93
Pharmaceutical Retail Sector
93
Company Profile
96
Bumimedic
96
Kotra Pharma
98
Pfizer
101
Pharmaniaga
104
Prime Pharmaceutical
108
Hovid
110
Chemical Company Of Malaysia
113
GlaxoSmithKline
116
Novartis
120
Merck & Co
123
Sanofi
126
Eli Lilly Malaysia
128
Ranbaxy Malaysia
130
Demographic Forecast
132
Demographic Outlook
132
Table: Malaysia's Population By Age Group, 1990-2020 ('000)
133
Table: Malaysia's Population By Age Group, 1990-2020 (% of total)
134
Table: Malaysia's Key Population Ratios, 1990-2020
135
Table: Malaysia's Rural And Urban Population, 1990-2020
135
Glossary
136
Methodology
138
Pharmaceutical Expenditure Forecast Model
138
Healthcare Expenditure Forecast Model
138
Notes On Methodology
139
Risk/Reward Ratings Methodology
140
Ratings Overview
141
Table: Pharmaceutical Risk/Reward Ratings Indicators
141
Indicator Weightings
142

The Malaysia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Malaysia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Malaysia pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Malaysia, to test other views - a key input for successful budgeting and strategic business planning in the Malaysian pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Malaysian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Malaysia.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc